Sarclisa Approved in the EU as First Anti-CD38 Therapy in Combination with Standard of Care VRd to Treat Transplant-Ineligible Newly Diagnosed Multiple Myeloma
Sarclisa Approved in the EU: A Milestone in Multiple Myeloma Treatment Introduction Recently, Sarclisa received approval in the European Union as the first anti-CD38 therapy to be used in combination with standard-of-care VRd for the treatment of transplant-ineligible newly diagnosed multiple myeloma patients. This marks a significant milestone in the field of oncology and provides…